spacer
home > pmps > summer 2009 > hands to the pump
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Hands to the Pump

Traditionally, nasal drug delivery was dedicated to the field of local treatment of nasal infections and allergies. In the early 1970s, the first mechanical spray pump delivering a metered dose was introduced to the market. The drug product was a corticosteroid formulation to treat allergic rhinitis and the common cold. Over the years, delivery devices have been optimised in terms of reliability and patient ease of use.

In parallel with the development of spray dispensing systems, delivery via the nasal mucosa proved to be an attractive alternative to injections. This was particularly true for therapies requiring fast onset of action, such as for pain management during crisis treatment. As a result, the nasal route has become the focus of extensive research and development activities, and many systemically acting drug products are now marketed. Irrespective of the therapeutic benefit, the nasal route offers the possibility to generate interesting intellectual property rights which can lead to a unique market position and to competitive advantage.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Hervé Pacaud has over 20 years’ experience in drug delivery devices. After joining Valois Pharma, Hervé took responsibility for sales in Europe and, more recently, in China, where he was in charge of the Asia Pacific region. He is now Director of Business Development and has global responsibility for the development of the sales of Valois Pharma’s spray pump line of products. Hervé graduated in Sales and Marketing from the University of Amiens, France.
spacer
Hervé Pacaud
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement